Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 3/20 | 0.48 |
| ▸ | CPA3 | P15088 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104253 | 1.00 | ALPI (0.57) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL27925911 | 0.85 | LDHA (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL9833991 | 0.83 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL27300438 | 0.83 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1532407 | 0.83 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7349956 | 0.83 | CYP1A2 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL392827 | 0.83 | CYP1A2 (0.70) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7274790 | 0.82 | MDM2 (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7274800 | 0.82 | MDM2 (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL16344520 | 0.82 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324975-A2 | DYNAMIC RESOLUTION OF ISOMERS AND RESOLVED ISOMERS | Bristol-Myers Squibb Company (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020111512-A1 | Dynamic resolution of isomers and resolved isomers | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | claimed |
| WO-2002028809-A2 | DYNAMIC RESOLUTION OF ISOMERS AND RESOLVED ISOMERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | claimed |
| US-7388098-B2 | Dynamic resolution of isomers and resolved isomers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1324975-B1 | DYNAMIC RESOLUTION OF ISOMERS AND RESOLVED ISOMERS | BRISTOL MYERS SQUIBB CO (US) | 2005-11-16 | — | — | EP | disclosed |
| CN-1639109-A | Kinetic resolution of isomers and resolved isomers | BRISTOL MYERS SQUIBB CO (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1140818-B1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMA INC (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1324975-A2 | DYNAMIC RESOLUTION OF ISOMERS AND RESOLVED ISOMERS | Bristol-Myers Squibb Company (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20020111512-A1 | Dynamic resolution of isomers and resolved isomers | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
| WO-2002028809-A2 | DYNAMIC RESOLUTION OF ISOMERS AND RESOLVED ISOMERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
| US-6329550-B1 | FOR THERAPY OF EMPHYSEMA, OSTEOPOROSIS, RHEUMATOID ARTHRITIS AND NEOPLASTIC DISEASES | AVENTIS PHARMACEUTICALS INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1140818-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040552-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| CN-1110865-A | Amino acid derivatives | EISAI CO LTD (JP) | 1995-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111512-A1 | Dynamic resolution of isomers and resolved isomers | DHCR24, LPAR1, SLC7A1 | ALPI 1764/4885PKM 4224/4885PTGS1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.